Men who reported sleep problems, including difficulty falling asleep and staying asleep, had up to a twofold increased risk for prostate cancer, according to recently published data.
For older men with nonmetastatic prostate cancer, comorbidities increase risk of other-cause death mortality.
Additional therapy may be needed for patients with advanced bladder cancers that are surgically removed. A five-year, international study validated the use of a marker panel to predict which patients are more likely to have a recurrence of cancer after bladder removal.
Men with prostate cancer who used statin drugs prior to diagnosis had a decreased risk of prostate-cancer-specific mortality.
Placing a stent within the aorta facilitated the subsequent removal of a tumor in the aorta and eliminated the need for heart-lung bypass for research patients.
Increased polyp and adenoma detection rates are associated with use of full-spectrum endoscopy colonoscope.
High fitness has been linked to reductions in risk of developing and dying from lung, colorectal cancer.
A new tool helps identify men who are best suited for active surveillance of prostate cancer, predicting which are more likely to harbor an aggressive form of the disease.
Time to tumor growth proved to be the best metric for predicting overall survival in persons with metastatic colorectal cancer on bevacizumab.
Findings from a phase I study of concurrent ipilimumab and nivolumab for advanced melanoma
Orally administered rigosertib was found to be well-tolerated in patients with advanced solid tumors in a phase 1 trial. Rigosertib is a dual kinase inhibitor, and this trial is the first to study its orally administered form in solid tumors.
Later-stage breast cancers tend to have more mutations and are more heterogeneous than early-stage cancers. Now, new findings demonstrate that heterogeneity is prevalent even within legions of DCIS.
A new chemotherapy regimen appears to produce minimal side effects in patients with lung cancer that has not responded to previous therapy, paving the way for additional research to determine if the new regimen also helps shrink tumors.
An irregularity within many neuroblastoma cells may indicate whether a neuroblastoma tumor is vulnerable to a new class of anti-cancer drugs known as BET bromodomain inhibitors.
Seemingly benign differences in genetic code from one person to the next could influence who develops side effects to chemotherapy. A new study identified gene variations that can predispose people to chemotherapy-induced peripheral neuropathy.
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|